Login to Your Account



Cancer drug demonstrates value for QED; $65M from Bridgebio fuels FGFR effort

By Randy Osborne
Staff Writer

Tuesday, January 30, 2018

Bridgebio Pharma Inc.'s asset hunter Michael Henderson told BioWorld his firm "came a bit late in the game" when attempting to grab a phase II cancer asset that Novartis AG no longer wanted, but officials "burned some nights and weekends" to win.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription